Base de dados : MEDLINE
Pesquisa : D01.146.307 [Categoria DeCS]
Referências encontradas : 144 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 15 ir para página                         

  1 / 144 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28181101
[Au] Autor:Sato T; Kikuchi M; Aizawa M
[Ad] Endereço:Department of Applied Chemistry, Graduated School of Science and Technology, Meiji University, Kawasaki, 214-8571, Japan.
[Ti] Título:Preparation of hydroxyapatite/collagen injectable bone paste with an anti-washout property utilizing sodium alginate. Part 1: influences of excess supplementation of calcium compounds.
[So] Source:J Mater Sci Mater Med;28(3):49, 2017 Mar.
[Is] ISSN:1573-4838
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The anti-washout property, viscosity, and cytocompatibility to an osteoblastic cell line, MG-63, of anti-washout pastes were investigated. Mixing a hydroxyapatite/collagen bone-like nanocomposite (HAp/Col), an aqueous solution of sodium alginate (Na-Alg), which is a paste hardening and lubricant agent, and supplementation of calcium carbonate or calcium citrate (Ca-Cit) as a calcium resource for the hardening reaction realized an injectable bone paste. Adding Ca-Cit at a concentration greater than eight times the Ca ion concentration to Na-Alg improved the anti-washout property. Although the viscosity test indicated a gradual increase in the paste viscosity as the calcium compounds increased, pastes with excess supplementation of calcium compounds exhibited injectability through a syringe with a 1.8 mm inner diameter, realizing an injectable bone filler. Furthermore, the anti-washout pastes with Ca-Cit had almost the same cell proliferation rate as that of the HAp/Col dense body. Therefore, HAp/Col injectable anti-washout pastes composed of the HAp/Col, Na-Alg, and Ca-Cit are potential candidates for bioresorbable bone filler pastes.
[Mh] Termos MeSH primário: Materiais Biocompatíveis/química
Substitutos Ósseos/química
Cálcio/química
Colágeno/química
Durapatita/química
[Mh] Termos MeSH secundário: Alginatos/química
Cimentos para Ossos
Reabsorção Óssea
Osso e Ossos/metabolismo
Carbonato de Cálcio/química
Citrato de Cálcio/química
Linhagem Celular Tumoral
Proliferação Celular
Ácido Glucurônico/química
Ácidos Hexurônicos/química
Seres Humanos
Íons
Teste de Materiais
Nanocompostos/química
Pós
Viscosidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alginates); 0 (Biocompatible Materials); 0 (Bone Cements); 0 (Bone Substitutes); 0 (Hexuronic Acids); 0 (Ions); 0 (Powders); 8A5D83Q4RW (Glucuronic Acid); 8C3Z4148WZ (alginic acid); 9007-34-5 (Collagen); 91D9GV0Z28 (Durapatite); H0G9379FGK (Calcium Carbonate); MLM29U2X85 (Calcium Citrate); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171021
[Lr] Data última revisão:
171021
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170210
[St] Status:MEDLINE
[do] DOI:10.1007/s10856-017-5853-3


  2 / 144 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28104108
[Au] Autor:Afshan S; Farah Musa AR; Echols V; Lerant AA; Fülöp T
[Ad] Endereço:Department of Pediatrics, University of Mississippi Medical Center, Jackson, Mississippi.
[Ti] Título:Persisting Hypocalcemia After Surgical Parathyroidectomy: The Differential Effectiveness of Calcium Citrate Versus Calcium Carbonate With Acid Suppression.
[So] Source:Am J Med Sci;353(1):82-86, 2017 Jan.
[Is] ISSN:1538-2990
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The effectiveness of oral calcium (Ca) may be contingent on a patient׳s factors beyond compliance, such as proton-pump inhibitor use and the choice of calcium supplements. A 32-year-old Hispanic male with end-stage renal disease on peritoneal dialysis underwent successful surgical parathyroidectomy (intact parathyroid hormone level: 2,328pg/mL; postsurgical: 287-69pg/mL [normal: 8.5-72.5]). His postoperative course was complicated by severe and recurrent hypocalcemia as outpatient and he needed repeated admissions for intravenous Ca gluconate. Initially, severe hypocalcemia (corrected Ca: 4.8-5.6mg/dL; nadir ionized Ca: 0.57-0.69mmol/L) was attributed solely to medical noncompliance with oral Ca carbonate (3750mg, 3×/day between meals) and calcitriol (2-4mcg/day). Recognizing coexisting treatment with proton-pump inhibitor, oral Ca supplement was changed to calcium citrate (2,850mg, 3×/day) with prompt resolution of hypocalcemia (corrected Ca: 8.1-8.3mg/dL). This current case and the included literature review emphasize the disproportionate effectiveness of Ca citrate in subjects with achlorhydria.
[Mh] Termos MeSH primário: Carbonato de Cálcio/uso terapêutico
Citrato de Cálcio/uso terapêutico
Hipocalcemia/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Interações Medicamentosas
Seres Humanos
Falência Renal Crônica/cirurgia
Falência Renal Crônica/terapia
Masculino
Paratireoidectomia/efeitos adversos
Inibidores da Bomba de Prótons/uso terapêutico
Diálise Renal
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Proton Pump Inhibitors); H0G9379FGK (Calcium Carbonate); MLM29U2X85 (Calcium Citrate)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170523
[Lr] Data última revisão:
170523
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170121
[St] Status:MEDLINE


  3 / 144 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27730307
[Au] Autor:Turudic D; Batinic D; Golubic AT; Lovric M; Milosevic D
[Ad] Endereço:University of Zagreb School of Medicine, Salata 3, 10000, Zagreb, Croatia.
[Ti] Título:Calcium oxalate urolithiasis in children: urinary promoters/inhibitors and role of their ratios.
[So] Source:Eur J Pediatr;175(12):1959-1965, 2016 Dec.
[Is] ISSN:1432-1076
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Diagnostic criteria for determination of inclination towards idiopathic calcium oxalate (CaOx) urolithiasis based on biochemical urine parameters are not sufficiently well defined in children. The aim of this study was to determine the risk of CaOx urolithiasis in children from concentrations of calcium, oxalate, citrate, and glycosaminoglycans in urine and their ratios, all standardized in respect to creatinine. We collected and analyzed 24-h urine samples of children with CaOx urolithiasis (n = 61) and compared with urine samples of matched control group of healthy children (n = 25). The study has showed that all stone formers have higher excretion of calcium (mmol/mmol creatinine), calcium/citrate (mol/mmol), and oxalate/(citrate × glycosaminoglycans) ratio (mol Ox × mol cr)/(mol Cit × g GAGs). ROC analysis of these variables gave criteria (>0.28, >1.07, and >0.08, respectively) for distinguishing stone formers from healthy children. Biochemical urine parameters and their ratios (calcium, calcium citrate, and oxalate/(citrate × glycosaminoglycans) enable one to discriminate idiopathic calcium oxalate stone formers from healthy children. Oxalate/(citrate × glycosaminoglycans) ratio per se can serve as an independent risk for stone formation. CONCLUSION: Using biochemical urine parameters and their ratios such as calcium, calcium/citrate, and oxalate/(citrate × glycosaminoglycans) enables one to determine diagnostic criteria towards idiopathic calcium oxalate urolithiasis in children. What is known: • The role of urine calcium as a promoter in calcium oxalate urolithiasis is well established. • Seldom used calcium/citrate ratio is acknowledged as a risk factor for calcium/oxalate urolithiasis. What is new: • The values of calcium and citrate in clinically and genetically proven idiopathic calcium oxalate urolithiasis make calcium/citrate ratio useful for diagnostic purposes in such stone formers. • Rarely used calcium independent oxalate/(citrate x glycosaminoglycans) ratio serves as the second best high specificity marker for idiopathic calcium oxalate urolithiasis.
[Mh] Termos MeSH primário: Oxalato de Cálcio/urina
Urolitíase/urina
[Mh] Termos MeSH secundário: Cálcio/urina
Citrato de Cálcio/urina
Estudos de Casos e Controles
Criança
Pré-Escolar
Feminino
Seres Humanos
Masculino
Curva ROC
Fatores de Risco
Estatísticas não Paramétricas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
2612HC57YE (Calcium Oxalate); MLM29U2X85 (Calcium Citrate); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171006
[Lr] Data última revisão:
171006
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161013
[St] Status:MEDLINE


  4 / 144 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27710434
[Au] Autor:Li J; Liu Y; Gao Y; Zhong L; Zou Q; Lai X
[Ad] Endereço:a College of Materials, Chemistry & Chemical Engineering, Chengdu University of Technology , Chengdu, Sichuan , P.R. China.
[Ti] Título:Preparation and properties of calcium citrate nanosheets for bone graft substitute.
[So] Source:Bioengineered;7(5):376-381, 2016 Sep 02.
[Is] ISSN:2165-5987
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A convenient and effective soft chemical method is presented for the synthesis of nano-scaled calcium citrate sheets. The preparation involved the precipitation of nano-calcium citrate by adding ethanol to reach the super saturation state of a solution containing calcium and citrate salts. The obtained nano-calcium citrate formed nanosheets, with the following dimensions: width of about 50∼500 nm and thickness of about 8∼30 nm. The results of the XRD analysis confirmed that the obtained sample is calcium citrate tetrahydrate, and the crystal degree decreased with an increase quantity of ethanol added. Animal experiments showed that the calcium citrate can promote the formation of new bone.
[Mh] Termos MeSH primário: Substitutos Ósseos/química
Citrato de Cálcio/química
Nanoestruturas/química
[Mh] Termos MeSH secundário: Animais
Seres Humanos
Modelos Animais
Modelos Teóricos
Espectroscopia de Infravermelho com Transformada de Fourier
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bone Substitutes); MLM29U2X85 (Calcium Citrate)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:171006
[Lr] Data última revisão:
171006
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161007
[St] Status:MEDLINE


  5 / 144 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo SciELO Brasil
[PMID]:27286123
[Au] Autor:Oguz U; Takci Z; Oguz ID; Resorlu B; Balta I; Unsal A
[Ad] Endereço:Department of Urology, School of Medicine, University Giresun, Giresun, Turkey.
[Ti] Título:Are patients with lichen planus really prone to urolithiasis? Lichen planus and urolithiasis.
[So] Source:Int Braz J Urol;42(3):571-7, 2016 May-Jun.
[Is] ISSN:1677-6119
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:PURPOSE: to investigate whether patients with lichen planus (LP) are really prone to urolithiasis or not. PATIENTS AND METHODS: We performed a prospective analysis of 40 patients diagnosed with lichen planus (LP) (group I), and 40 volunteers did not have LP before (group II). Participants were all checked for urolithiasis by radiological investigations. Blood samples were analyzed for biochemistry parameters including calcium and uric acid. 24-h urine samples were analyzed to investigate oxalate, citrate calcium, uric acid, magnesium, sodium and creatinine. RESULTS: Men/women ratio and mean age were similar between group I and II (p>0.05). A presence or history of urolithiasis was detected in 8 (20%) and 2 (%5) patients in group I and II, respectively (p<0.05). Hypocitraturia was the most common anomaly with 35% (n:14) in group I. The rate of hypocitraturia in group II was 12.5% (n:5) and the difference was statistically significantly different (p=0.036). In group I, hyperuricosuria and hyperoxaluria followed with rates of 27.5% (n:11) and 25% (n:10), respectively. The rate of hyperuricosuria and hyperoxaluria were both 5% (n:2) in group II and the differences were significant (p<0.05). Hyperuricemia was another importante finding in the patients with LP. It was detected in 13 (32.5%) patients in group I and in 1 (2.5%) participant in group II (p=0.001). CONCLUSION: According to our results, metabolic disorders of urolithiasis were highly detected in the patients with LP. However, similar to the etiology of LP, the exact reasons for these metabolic abnormalities in LP remain a mystery.
[Mh] Termos MeSH primário: Líquen Plano/complicações
Urolitíase/etiologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Cálcio/sangue
Citrato de Cálcio/urina
Estudos de Casos e Controles
Creatinina/urina
Feminino
Seres Humanos
Líquen Plano/urina
Magnésio/urina
Masculino
Doenças Metabólicas/complicações
Doenças Metabólicas/urina
Meia-Idade
Oxalatos/urina
Estudos Prospectivos
Valores de Referência
Fatores de Risco
Sódio/urina
Ácido Úrico/sangue
Ácido Úrico/urina
Urinálise
Urolitíase/urina
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Oxalates); 268B43MJ25 (Uric Acid); 9NEZ333N27 (Sodium); AYI8EX34EU (Creatinine); I38ZP9992A (Magnesium); MLM29U2X85 (Calcium Citrate); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160611
[St] Status:MEDLINE


  6 / 144 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26493812
[Au] Autor:Bristow SM; Gamble GD; Pasch A; O'Neill WC; Stewart A; Horne AM; Reid IR
[Ad] Endereço:University of Auckland, Auckland, New Zealand.
[Ti] Título:Acute and 3-month effects of calcium carbonate on the calcification propensity of serum and regulators of vascular calcification: secondary analysis of a randomized controlled trial.
[So] Source:Osteoporos Int;27(3):1209-1216, 2016 Mar.
[Is] ISSN:1433-2965
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:SUMMARY: Calcium supplements have been associated with increased cardiovascular risk, but the mechanism is unknown. We investigated the effects of calcium supplements on the propensity of serum to calcify, based on the transition time of primary to secondary calciprotein particles (T50). Changes in serum calcium were related to changes in T50. INTRODUCTION: Calcium supplements have been associated with increased cardiovascular risk; however, it is unknown whether this is related to an increase in vascular calcification. METHODS: We investigated the acute and 3-month effects of calcium supplements on the propensity of serum to calcify, based on the transition time of primary to secondary calciprotein particles (T50), and on three possible regulators of calcification: fetuin-A, pyrophosphate and fibroblast growth factor-23 (FGF23). We randomized 41 postmenopausal women to 1 g/day of calcium as carbonate, or to a placebo containing no calcium. Measurements were performed at baseline and then 4 and 8 h after their first dose, and after 3 months of supplementation. Fetuin-A, pyrophosphate and FGF23 were measured in the first 10 participants allocated to calcium carbonate and placebo who completed the study. RESULTS: T50 declined in both groups, the changes tending to be greater in the calcium group. Pyrophosphate declined from baseline in the placebo group at 4 h and was different from the calcium group at this time point (p = 0.04). There were no other significant between-groups differences. The changes in serum total calcium from baseline were significantly related to changes in T50 at 4 h (r = -0.32, p = 0.05) and 8 h (r = -0.39, p = 0.01), to fetuin-A at 3 months (r = 0.57, p = 0.01) and to pyrophosphate at 4 h (r = 0.61, p = 0.02). CONCLUSIONS: These correlative findings suggest that serum calcium concentrations modulate the propensity of serum to calcify (T50), and possibly produce counter-regulatory changes in pyrophosphate and fetuin-A. This provides a possible mechanism by which calcium supplements might influence vascular calcification.
[Mh] Termos MeSH primário: Conservadores da Densidade Óssea/efeitos adversos
Carbonato de Cálcio/efeitos adversos
Citrato de Cálcio/efeitos adversos
Suplementos Nutricionais/efeitos adversos
Calcificação Vascular/induzido quimicamente
[Mh] Termos MeSH secundário: Idoso
Biomarcadores/sangue
Conservadores da Densidade Óssea/administração & dosagem
Cálcio/sangue
Carbonato de Cálcio/administração & dosagem
Citrato de Cálcio/administração & dosagem
Difosfatos/sangue
Esquema de Medicação
Feminino
Fatores de Crescimento de Fibroblastos/sangue
Seres Humanos
Meia-Idade
Calcificação Vascular/sangue
alfa-2-Glicoproteína-HS/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Biomarkers); 0 (Bone Density Conservation Agents); 0 (Diphosphates); 0 (alpha-2-HS-Glycoprotein); 0 (fibroblast growth factor 23); 4E862E7GRQ (diphosphoric acid); 62031-54-3 (Fibroblast Growth Factors); H0G9379FGK (Calcium Carbonate); MLM29U2X85 (Calcium Citrate); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151024
[St] Status:MEDLINE
[do] DOI:10.1007/s00198-015-3372-y


  7 / 144 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24251429
[Au] Autor:Iqbal MW; Youssef RF; Neisius A; Kuntz N; Hanna J; Ferrandino MN; Preminger GM; Lipkin ME
[Ad] Endereço:1 Division of Urologic Surgery, Duke University Medical Center , Durham, North Carolina.
[Ti] Título:Contemporary Management of Struvite Stones Using Combined Endourologic and Medical Treatment: Predictors of Unfavorable Clinical Outcome.
[So] Source:J Endourol;30(7):771-7, 2016 Jul.
[Is] ISSN:1557-900X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND PURPOSE: Struvite stones have been associated with significant morbidity and mortality, yet there has not been a report on the medical management of struvite stones in almost 20 years. We report on the contemporary outcomes of the surgical and medical management of struvite stones in a contemporary series. PATIENTS AND METHODS: A retrospective review of patients who were treated with percutaneous nephrolithotomy (PCNL) for struvite stones at Duke University Medical Center between January 2005 and September 2012 identified a total of 75 patients. Of these, 43 patients had adequate follow-up and were included in this analysis. Stone activity, defined as either stone recurrence or stone-related events, and predictors of activity were evaluated after combined surgical and medical treatment. RESULTS: The study included 43 patients with either pure (35%) or mixed (65%) struvite stones with a median age of 55±15 years (range 21-89 years). The stone-free rate after PCNL was 42%. Stone recurrence occurred in 23% of patients. Postoperatively, 30% of patients had a stone-related event, while 60% of residual stones remained stable with no growth after a median follow-up of 22 months (range 6-67 mos). Kidney function remained stable during follow-up. Independent predictors of stone activity included the presence of residual stones >0.4 cm(2), preoperative large stone burden (>10 cm(2)), and the presence of medical comorbidities (P<0.05). CONCLUSIONS: Struvite stones can be managed safely with PCNL followed by medical therapy. The majority of patients with residual fragments demonstrated no evidence of stone growth on medical therapy. With careful follow-up and medical management, kidney function can be maintained and stone morbidity can be minimized. Initial large stone burden, residual stones after surgery, and associated medical comorbidities may have deleterious effect on stone recurrence or residual stone-related events.
[Mh] Termos MeSH primário: Cálculos Renais/terapia
Nefrostomia Percutânea/métodos
Estruvita
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Antibacterianos/uso terapêutico
Citrato de Cálcio
Clortalidona
Comorbidade
Diuréticos/uso terapêutico
Inibidores Enzimáticos/uso terapêutico
Feminino
Seres Humanos
Ácidos Hidroxâmicos/uso terapêutico
Masculino
Meia-Idade
Complicações Pós-Operatórias/epidemiologia
Citrato de Potássio/uso terapêutico
Recidiva
Estudos Retrospectivos
Bicarbonato de Sódio
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Diuretics); 0 (Enzyme Inhibitors); 0 (Hydroxamic Acids); 4RZ82L2GY5 (acetohydroxamic acid); 8MDF5V39QO (Sodium Bicarbonate); AW3EJL1462 (Struvite); EE90ONI6FF (Potassium Citrate); MLM29U2X85 (Calcium Citrate); Q0MQD1073Q (Chlorthalidone)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170816
[Lr] Data última revisão:
170816
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:131121
[St] Status:MEDLINE
[do] DOI:10.1089/end.2013.0257


  8 / 144 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo SciELO Brasil
[PMID]:26537273
[Au] Autor:Baretta GA; Cambi MP; Rodrigues AL; Mendes SA
[Ad] Endereço:Vita Batel Hospital, Curitiba, PR, Brazil.
[Ti] Título:SECONDARY HYPERPARATHYROIDISM AFTER BARIATRIC SURGERY: TREATMENT IS WITH CALCIUM CARBONATE OR CALCIUM CITRATE?
[So] Source:Arq Bras Cir Dig;28 Suppl 1:43-5, 2015.
[Is] ISSN:2317-6326
[Cp] País de publicação:Brazil
[La] Idioma:eng; por
[Ab] Resumo:BACKGROUND: Bariatric surgery, especially Roux-en-Y gastric bypass, can cause serious nutritional complications arising from poor absorption of essential nutrients. Secondary hyperparathyroidism is one such complications that leads to increased parathyroid hormone levels due to a decrease in calcium and vitamin D, which may compromise bone health. AIM: To compare calcium carbonate and calcium citrate in the treatment of secondary hyperparathyroidism. METHOD: Patients were selected on the basis of their abnormal biochemical test and treatment was randomly done with citrate or calcium carbonate. RESULTS: After 60 days of supplementation, biochemical tests were repeated, showing improvement in both groups. CONCLUSION: Supplementation with calcium (citrate or carbonate) and vitamin D is recommended after surgery for prevention of secondary hyperparathyroidism.
[Mh] Termos MeSH primário: Cirurgia Bariátrica/efeitos adversos
Carbonato de Cálcio/uso terapêutico
Citrato de Cálcio/uso terapêutico
Hiperparatireoidismo Secundário/tratamento farmacológico
Hiperparatireoidismo Secundário/etiologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Feminino
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
H0G9379FGK (Calcium Carbonate); MLM29U2X85 (Calcium Citrate)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:160322
[Lr] Data última revisão:
160322
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151106
[St] Status:MEDLINE


  9 / 144 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26420590
[Au] Autor:Bristow SM; Gamble GD; Stewart A; Horne AM; Reid IR
[Ad] Endereço:Department of Medicine,University of Auckland,Private Bag 92 019,Auckland 1142,New Zealand.
[Ti] Título:Acute effects of calcium supplements on blood pressure and blood coagulation: secondary analysis of a randomised controlled trial in post-menopausal women.
[So] Source:Br J Nutr;114(11):1868-74, 2015 Dec 14.
[Is] ISSN:1475-2662
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Recent evidence suggests that Ca supplements increase the risk of cardiovascular events, but the mechanism(s) by which this occurs is uncertain. In a study primarily assessing the effects of various Ca supplements on blood Ca levels, we also investigated the effects of Ca supplements on blood pressure and their acute effects on blood coagulation. We randomised 100 post-menopausal women to 1 g/d of Ca or a placebo containing no Ca. Blood pressure was measured at baseline and every 2 h up to 8 h after their first dose and after 3 months of supplementation. Blood coagulation was measured by thromboelastography (TEG) in a subgroup of participants (n 40) up to 8 h only. Blood pressure declined over 8 h in both the groups, consistent with its normal diurnal rhythm. The reduction in systolic blood pressure was smaller in the Ca group compared with the control group by >5 mmHg between 2 and 6 h (P≤0·02), and the reduction in diastolic blood pressure was smaller at 2 h (between-groups difference 4·5 mmHg, P=0·004). Blood coagulability, assessed by TEG, increased from baseline over 8 h in the calcium citrate and control groups. At 4 h, the increase in the coagulation index was greater in the calcium citrate group compared with the control group (P=0·03), which appeared to be due to a greater reduction in the time to clot initiation. These data suggest that Ca supplements may acutely influence blood pressure and blood coagulation. Further investigation of this possibility is required.
[Mh] Termos MeSH primário: Transtornos da Coagulação Sanguínea/etiologia
Conservadores da Densidade Óssea/efeitos adversos
Citrato de Cálcio/efeitos adversos
Cálcio na Dieta/efeitos adversos
Suplementos Nutricionais/efeitos adversos
Fenômenos Fisiológicos da Nutrição do Idoso
Hipertensão/etiologia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Coagulação Sanguínea
Transtornos da Coagulação Sanguínea/epidemiologia
Pressão Sanguínea
Conservadores da Densidade Óssea/administração & dosagem
Conservadores da Densidade Óssea/uso terapêutico
Carbonato de Cálcio/efeitos adversos
Carbonato de Cálcio/uso terapêutico
Citrato de Cálcio/uso terapêutico
Cálcio na Dieta/administração & dosagem
Cálcio na Dieta/uso terapêutico
Estudos de Coortes
Método Duplo-Cego
Durapatita/efeitos adversos
Durapatita/uso terapêutico
Feminino
Seres Humanos
Hipertensão/epidemiologia
Meia-Idade
Nova Zelândia/epidemiologia
Osteoporose Pós-Menopausa/epidemiologia
Osteoporose Pós-Menopausa/prevenção & controle
Pacientes Desistentes do Tratamento
Risco
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Bone Density Conservation Agents); 0 (Calcium, Dietary); 91D9GV0Z28 (Durapatite); H0G9379FGK (Calcium Carbonate); MLM29U2X85 (Calcium Citrate)
[Em] Mês de entrada:1602
[Cu] Atualização por classe:151105
[Lr] Data última revisão:
151105
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151001
[St] Status:MEDLINE
[do] DOI:10.1017/S0007114515003694


  10 / 144 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26258559
[Au] Autor:Liu J; Wang Y; Song S; Wang X; Qin Y; Si S; Guo Y
[Ad] Endereço:Key Laboratory of Photochemical Conversion and Optoelectronic Materials, Technical Institute of Physics and Chemistry, Chinese Academy of Science, Beijing, People's Republic of China; Center for Special Medicine and Experimental Research, 306 Hospital of PLA, Beijing, People's Republic of China.
[Ti] Título:Combined oral administration of bovine collagen peptides with calcium citrate inhibits bone loss in ovariectomized rats.
[So] Source:PLoS One;10(8):e0135019, 2015.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Collagen peptides (CPs) and calcium citrate are commonly used as bone health supplements for treating osteoporosis. However, it remains unknown whether the combination of oral bovine CPs with calcium citrate is more effective than administration of either agent alone. METHODS: Forty 12-week-old Sprague-Dawley rats were randomly divided into five groups (n = 8) for once-daily intragastric administration of different treatments for 3 months at 3 months after ovariectomy (OVX) as follows: sham + vehicle; OVX + vehicle; OVX + 750 mg/kg CP; OVX + CP-calcium citrate (75 mg/kg); OVX + calcium citrate (75 mg/kg). After euthanasia, the femurs were removed and analyzed by dual energy X-ray absorptiometry and micro-computed tomography, and serum samples were analyzed for bone metabolic markers. RESULTS: OVX rats supplemented with CPs or CP-calcium citrate showed osteoprotective effects, with reductions in the OVX-induced decreases in their femoral bone mineral density. Moreover, CP-calcium citrate prevented trabecular bone loss, improved the microarchitecture of the distal femur, and significantly inhibited bone loss with increased bone volume, connectivity density, and trabecular number compared with OVX control rats. CP or CP-calcium citrate administration significantly increased serum procollagen type I N-terminal propeptide levels and reduced serum bone-specific alkaline phosphatase, osteocalcin, and C-telopeptide of type I collagen levels. CONCLUSIONS: Our data indicate that combined oral administration of bovine CPs with calcium citrate inhibits bone loss in OVX rats. The present findings suggest that combined oral administration of bovine CPs with calcium citrate is a promising alternative for reducing bone loss in osteopenic postmenopausal women.
[Mh] Termos MeSH primário: Conservadores da Densidade Óssea/farmacologia
Citrato de Cálcio/farmacologia
Colágeno/farmacologia
Osteoporose/tratamento farmacológico
Ovariectomia
Peptídeos/farmacologia
[Mh] Termos MeSH secundário: Absorciometria de Fóton
Administração Oral
Fosfatase Alcalina/sangue
Animais
Densidade Óssea/efeitos dos fármacos
Bovinos
Colágeno Tipo I/sangue
Modelos Animais de Doenças
Combinação de Medicamentos
Feminino
Fêmur/diagnóstico por imagem
Fêmur/efeitos dos fármacos
Fêmur/metabolismo
Fêmur/patologia
Seres Humanos
Osteocalcina/sangue
Osteoporose/sangue
Osteoporose/diagnóstico por imagem
Osteoporose/patologia
Peptídeos/sangue
Ratos
Ratos Sprague-Dawley
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
0 (Bone Density Conservation Agents); 0 (Collagen Type I); 0 (Drug Combinations); 0 (Peptides); 0 (collagen type I trimeric cross-linked peptide); 104982-03-8 (Osteocalcin); 9007-34-5 (Collagen); EC 3.1.3.1 (Alkaline Phosphatase); MLM29U2X85 (Calcium Citrate)
[Em] Mês de entrada:1605
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150811
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0135019



página 1 de 15 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde